Search

Displaying results 2331 - 2340 of 10000 in total
  1. Drug

    Botulinum toxin type A

    go.drugbank.com/drugs/DB00083
    ApprovedInvestigational

    In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use. … [A231819,L32569] A popular use for Botox is the treatment of facial wrinkles and lines, however, there are many uses for the botulinum toxin A in the treatment of dystonia, incontinence, migraine, blepharospasm

    Categories: Botulinum Toxins, Type ASynonyms: BTX A, BTX-A
  2. Drug

    Perfluorohexyloctane

    go.drugbank.com/drugs/DB17823
    ApprovedInvestigational

    [A259746, A259751] Perfluorohexyloctane has been used in the field of ophthalmology as a vitreous substitute. … [A259746] Because it is a completely non-aqueous liquid, microbial growth is not possible; therefore, its drug products do not need to be combined with any preservative.

  3. Drug

    Elivaldogene autotemcel

    go.drugbank.com/drugs/DB16746
    Approved

    Elivaldogene autotemcel is a gene therapy consisting of genetically modified autologous cells. … Without sufficient levels of functional ALDP, VLCFAs accumulate in the body leading to inflammation and destruction of myelin, which is an insulating layer and essential component of nerves.

    International brands: Lenti-D
  4. Drug

    Lapyrium

    go.drugbank.com/drugs/DB09376
    Approved

    Lapyrium is a quaternary ammonium cation used as a surfactant, antistatic agent, and biocide in various cosmetic products [A19426]. It is commonly found formulated as lapyrium chloride.

  5. Indication

    Severe Pain

    go.drugbank.com/conditions/DBCOND0066540
    Drugs: Acetaminophen · Acetylsalicylic acid · Buprenorphine · Butorphanol · Cannabidiol · Codeine +23 more
  6. Drug

    Trabectedin

    go.drugbank.com/drugs/DB05109
    ApprovedInvestigational

    On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas. … Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery.

    Categories: Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index
  7. Drug

    Glofitamab

    go.drugbank.com/drugs/DB16371
    ApprovedInvestigational

    ], [vincristine], [prednisone])[L45763] - despite this, as many as 40% of patients will experience relapsed or refractory disease. … This approval is based on the positive results obtained from the phase I/II NP30179 study, where 35.2% of study participants achieved a complete response.[L47451]

  8. Drug

    Loncastuximab tesirine

    go.drugbank.com/drugs/DB16222
    ApprovedInvestigational

    Zylonta also received approval in the EU on December 22, 2022. … [A234444] On April 23 2021, the Food and Drug Administration granted accelerated approval for the antibody-drug conjugate, loncastuximab tesirine-lpyl, also known as Zynlonta.

    Synonyms: Humanized monoclonal immunoglobulin G1 antibody directed against human CD19 conjugated to SG3199 through A protease cleavable valine-alanine linker
  9. Drug

    Medical air

    go.drugbank.com/drugs/DB09337
    ApprovedInvestigationalVet approved

    Medical air is supplied by a special air compressor to patient care areas using clean outside air.

  10. Drug

    DaxibotulinumtoxinA

    go.drugbank.com/drugs/DB17929
    ApprovedInvestigational

    [L47870] DAXI or DAXXIFY, a product of daxibotulinumtoxinA, incorporates RTP004, a proprietary synthetic stabilizing peptide for enhanced product stability.[A261080, A261085] … [L47865] On August 14, 2023, the drug was also approved for the treatment of cervical dystonia.

    Categories: Botulinum Toxins, Type A